Profile data is unavailable for this security.
About the company
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.
- Revenue in EUR (TTM)6.60m
- Net income in EUR-6.87m
- Incorporated2006
- Employees47.00
- LocationMarinomed Biotech AGHovengasse 25KORNEUBURG 2100AustriaAUT
- Phone+43 226290300
- Fax+43 226 290300500
- Websitehttps://www.marinomed.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharmaceuticals, Inc. | 35.84m | -9.84m | 15.15m | 91.00 | -- | 0.6093 | -- | 0.4227 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Cosma SA | 915.23k | -10.89m | 15.31m | 31.00 | -- | 1.94 | -- | 16.72 | -0.4301 | -0.4301 | 0.0362 | 0.2343 | 0.0733 | 0.8409 | 3.05 | 136,278.60 | -87.24 | -- | -91.46 | -- | 58.45 | -- | -1,189.90 | -- | 0.5634 | -129.62 | 0.0119 | -- | -- | -- | -18,399.08 | -- | -- | -- |
| TherapeuticsMD Inc | 1.51m | -3.76m | 15.32m | 1.00 | -- | 0.5959 | -- | 10.12 | -0.3499 | -0.291 | 0.1399 | 2.35 | 0.0355 | -- | 0.4944 | 1,596,000.00 | -8.81 | -53.35 | -11.41 | -111.61 | 31.45 | 86.67 | -248.56 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Labiana Health SA | 65.09m | -1.18m | 15.45m | 363.00 | -- | 3.22 | 4.45 | 0.2374 | -0.1692 | -0.1692 | 9.27 | 0.6652 | 1.20 | 2.06 | 6.59 | 152,437.70 | -2.20 | -4.49 | -4.52 | -7.80 | 61.64 | 59.40 | -1.83 | -4.92 | 0.8015 | 0.9877 | 0.7459 | -- | 1.06 | 6.45 | 50.54 | -- | -9.47 | -- |
| Sotac Pharmaceuticals Ltd | 11.77m | 466.47k | 15.57m | 89.00 | 33.38 | 2.94 | 18.85 | 1.32 | 3.76 | 3.76 | 94.83 | 42.67 | 0.9762 | 4.92 | 3.77 | -- | 3.87 | -- | 7.26 | -- | 21.45 | -- | 3.96 | -- | 0.8132 | 2.77 | 0.3546 | -- | 79.07 | -- | -20.38 | -- | -- | -- |
| NicOx SA | -100.00bn | -100.00bn | 15.68m | 5.00 | -- | 0.7171 | -- | -- | -- | -- | -- | 0.3166 | -- | -- | -- | -- | -- | -22.59 | -- | -24.55 | -- | -- | -- | -337.85 | -- | -- | 0.5424 | -- | 26.59 | 11.38 | 33.26 | -- | -- | -- |
| Marinus Pharmaceuticals Inc | 29.85m | -133.27m | 15.77m | 165.00 | -- | -- | -- | 0.5283 | -2.47 | -2.47 | 0.5524 | -1.21 | 0.238 | 0.6542 | 7.75 | 190,703.00 | -106.26 | -49.64 | -140.93 | -57.76 | 90.17 | -- | -446.49 | -518.96 | 1.47 | -10.06 | -- | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| Marinomed Biotech AG | 6.60m | -6.87m | 16.10m | 47.00 | -- | -- | -- | 2.44 | -4.46 | -4.46 | 4.28 | -7.69 | -- | -- | -- | 140,468.10 | -- | -33.46 | -- | -48.73 | 10.56 | 7.67 | -103.99 | -69.70 | 1.46 | -4.51 | 2.20 | -- | -18.56 | 14.50 | -6.21 | -- | -10.92 | -- |
| Cara Therapeutics Inc | 8.24m | -90.62m | 16.19m | 55.00 | -- | 24.13 | -- | 1.96 | -1.75 | -1.75 | 0.1589 | 0.0129 | 0.1042 | 0.6312 | 4.59 | 157,927.30 | -114.63 | -35.76 | -142.84 | -40.82 | 56.44 | -- | -1,099.76 | -162.10 | 4.71 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Biofrontera AG | 21.67m | -2.57m | 16.74m | 80.00 | -- | 0.9376 | -- | 0.7725 | -0.4146 | -0.4146 | 3.81 | 2.94 | 0.8376 | 1.14 | 13.28 | 246,261.40 | -9.93 | -11.99 | -14.14 | -15.19 | 75.61 | 84.28 | -11.85 | -20.93 | 1.45 | -1.27 | 0.0494 | -- | 25.30 | 8.85 | 99.16 | -- | 12.20 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Erste Asset Management GmbHas of 28 Jun 2024 | 133.35k | 8.66% |
| Matejka & Partner Asset Management GmbHas of 28 Jun 2024 | 76.67k | 4.98% |
| LLB Invest Kapitalanlagegesellschaft mbHas of 13 Feb 2023 | 59.60k | 3.87% |
| 3 Banken-Generali Investment-Gesellschaft mbHas of 28 Jun 2024 | 20.40k | 1.32% |
| SK Verm�gensverwaltung GmbHas of 31 Mar 2024 | 14.77k | 0.96% |
| Sparkasse Ober�sterreich Kapitalanlagegesellschaft m.bH.as of 28 Jun 2024 | 11.45k | 0.74% |
| amandea Verm�gensverwaltung AGas of 31 Dec 2022 | 3.22k | 0.21% |
| Fund Development & Advisory AGas of 30 Jun 2024 | 1.65k | 0.11% |
| FINAD GmbHas of 31 Mar 2022 | 1.08k | 0.07% |
| Amundi Austria GmbHas of 30 Dec 2022 | 1.00k | 0.07% |
